Ceftolozane (sulfate)

[1]Moyá B, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Sep;54 (9) :3933-7.|[2]Moya B, et al. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010 Mar;54 (3) :1213-7.|[3]Kostoulias X, et al. Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions. J Antimicrob Chemother. 2025 Feb 3;80 (2) :372-380.|[4]Livermore DM, et al. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents. 2009 Nov;34 (5) :402-6.|[5]Juan C, et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2010 Feb;54 (2) :846-51.|[6]Craig WA, et al. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013 Apr;57 (4) :1577-82.|[7]Jacqueline C, et al. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response. J Antimicrob Chemother. 2013 Jan;68 (1) :177-83.